<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Relatively little data on <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary cancers</z:e> is available regarding patients treated for non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), compared with those treated for Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Evolving treatment regimens have improved survival outcomes for NHL patients </plain></SENT>
<SENT sid="2" pm="."><plain>As a result of this improvement, <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary malignancies</z:e> are becoming an important issue in NHL survivors </plain></SENT>
<SENT sid="3" pm="."><plain>This review aims to report data on this topic previously published by our group, adding unpublished results from the Modena <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry (MCR) </plain></SENT>
<SENT sid="4" pm="."><plain>We recently performed four studies about secondary <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in NHL survivors: two studies analysing the risk of secondary <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in patients treated for indolent and aggressive NHL; a meta-analysis of 23 studies investigating the risk of secondary malignant <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (SMN) after NHL treatment; and a still-unpublished study evaluating the incidence of therapy-related myeloid <z:hpo ids='HP_0002664'>neoplasm</z:hpo> (t-MN) in patients treated for NHL (from the MCR database) </plain></SENT>
<SENT sid="5" pm="."><plain>The first two studies analysed 563 patients with indolent NHL and 1280 patients with diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) enrolled in the Gruppo Italiano Studio Linfomi (GISL) trials </plain></SENT>
<SENT sid="6" pm="."><plain>Results showed that the cumulative incidence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">secondary tumours</z:e> was 10.5% at 12 years for indolent NHL and 8.2% at 15 years for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Results of the meta-analysis indicated that NHL patients experienced a 1.88-fold increased risk for SMN compared with the general population; the standardized incidence risk (SIR) for secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) was 11.07 </plain></SENT>
<SENT sid="8" pm="."><plain>Based on data from the MCR from 2000 through 2008, we found that the SIR was 1.63 for developing a <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">secondary malignancy</z:e> after NHL, and 1.99 for developing secondary <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Regarding <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> incidence, nine NHL patients developed t-MN with a higher risk than expected (SIR 8.8, 95% CI: 4.0-16.6) </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, patients treated for NHL are at increased risk of developing SMN </plain></SENT>
<SENT sid="11" pm="."><plain>Regarding t-MN, data from the meta-analysis and the MCR demonstrate an excessive risk of developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (SIR 11.07 and 5.7, respectively) compared with solid SMN after treatment for NHL </plain></SENT>
<SENT sid="12" pm="."><plain>Thus long-term monitoring should be considered for NHL survivors </plain></SENT>
</text></document>